Brian Noga

Chief Executive Officer 

Vidya Joshi, PhD

Chief Development Officer

Vidya Joshi, Ph.D., is the Chief Development Officer at Aerogen® Pharma, bringing over 27 years of extensive end-to-end pulmonary product development experience including pMDIs and DPIs for respiratory and systemic delivery. She played a pivotal role at AstraZeneca for 16 years, leading multiple global inhaled product programs from proof of concept to commercialization, including approvals for Breztri, Bevespi, Airsupra, and Symbicort Aerosphere in various global markets. She is a purpose-driven leader, energized by Aerogen Pharma’s mission to save premature babies not just in developed but also in low- and middle-income nations.
Most recently as Global Program Lead, she spearheaded AstraZeneca’s transition to a greener pMDI platform, overseeing a $200M budget, forging strategic alliances with Honeywell, and engaging key stakeholders at the White House, EPA, European environmental agencies, and the UN. Her regulatory ingenuity helped cut clinical program costs by over $100M through collaboration with the FDA.
Previously, at Pearl Therapeutics, she led CMC development for Breztri and Bevespi, co-authoring key formulation and product patents for AZ’s Aerosphere portfolio. Her career also includes key roles at Nektar Therapeutics, where she worked on Exubera product approval and next-generation inhaled insulin development, and Dura Pharmaceuticals, focusing on inhaled steroids and bronchodilator DPIs.
Vidya holds a BS in Pharmaceutical Sciences from the University of Bombay and a Ph.D. in Industrial and Physical Pharmacy from Purdue University.

Rob Jackson

Director of Commercial Strategy

Rob Jackson is the Director of Commercial Strategy at Aerogen® Pharma, where he plays a pivotal role in shaping the company’s commercial roadmap and priorities. With over 20 years of experience in the pharmaceutical and medical device industries across both US and international markets, Rob brings a wealth of experience and expertise to the team.
Prior to joining Aerogen Pharma, Rob served as the Senior Vice President of Sales & Marketing at RedHill Biopharma. During his tenure, he significantly enhanced the company’s commercial capabilities, led the launch of Talicia®, and led the commercial team's successful effort to acquire the US rights to AstraZeneca’s Movantik®. Prior to RedHill, Rob also led marketing and market access teams for Bioventus, Salix Pharmaceuticals, and Vicuron Pharmaceuticals. Earlier in his career, Rob was instrumental in leading the launch of Invanz® at Merck & Co., where he established the groundwork for a global anti-infective brand that surpassed $500 million in annual sales.
Rob’s education includes a BS in Biology from Fitchburg State University and an MBA from Ball State University.

Jim Fink, PhD, RRT, FAARC, FCCP

Chief Scientific Officer

Jim Fink serves as Chief Science Officer, where he spearheads the design requirements, implementation and applications of the aerosol delivery systems at the core of the Aerogen Pharma product pipeline.  An accomplished clinician, researcher and inventor, Jim has focused the last 35 years on developing innovative aerosol delivery options for treatment of critically ill patients. 
Prominent industry roles have included Sr. Fellow of Aerosol Device Development at Dance Biopharm (Brisbane, CA), Chief Clinical Officer at Aerogen Ltd. (Galway, Ireland), Fellow of Aerosol Science at Nektar Therapeutics (San Carlos, CA) and as consultant on inhalation technology to the drug development industry. 
Jim holds more than 40 patents and published more than180 peer reviewed papers. He is a fellow of the AARC, ACCP and ISAM.  Jim has a PhD in Pharmaceutical Innovation from Bradford University, UK.

David Durand MD

Chief Medical Officer

David Durand, MD serves as our Chief Medical Officer where he leads the design and conduct of clinical trials. Before joining Aerogen Pharma, David worked as a physician leader and hospital administrator at what is now UCSF Benioff Children’s Hospital Oakland. He spent almost 30 years as a neonatologist, including work at the bedside caring for infants in the level IV NICU, as a clinical research scientist, teacher, and as Director of Neonatology. He was subsequently recruited to be the Chief Medical Officer and spent over 6 years working in senior administration at Children’s and in the UCSF system where much of his work focused on the affiliation of the Children’s Hospital in Oakland into the UCSF system.
Dr Durand’s primary academic interest has been lung-protective strategies for the respiratory support of critically ill infants. He has published multiple articles in peer reviewed journals, has authored more than 25 chapters in textbooks of neonatology, and has spoken widely at national and international academic conferences. He has served as the president of the California Association of Neonatologists, and was a founding board member of the Children’s Hospitals’ Neonatal Consortium, an international benchmarking, quality, and research organization.
Dr Durand has an undergraduate degree in biology from the University of San Francisco, and MD degree from the Medical College of Wisconsin, did his pediatric internship and residency at Children’s Hospital Oakland, and did his fellowship in neonatal-perinatal medicine at Mt Zion Hospital in San Francisco (now part of UCSF).

Carmen Jacome 

Director of Program Management 

Carmen Jacome is the Director of Program Management at Aerogen Pharma, where she spearheads the development and implementation of advanced program management tools to support the delivery of pharmaceutical development and commercialization programs across all phases.
With over 20 years of experience, Carmen is a versatile leader who has successfully guided cross-functional teams from late discovery through clinical development, approval, and commercialization. Her career spans from early-stage startups to large biopharmaceutical companies.
Prior to joining Aerogen Pharma, Carmen served as the VP of Program Management at Ascidian Therapeutics, where she led the portfolio and program management for Ascidian’s pioneering RNA exon editing platform. She has also held progressively responsible program management roles at Pfizer, Novartis, Thrombogenics, Cempra Pharmaceuticals, and Flexion Therapeutics.
Carmen holds a BS in Computer Science from Escuela Superior Politécnica in Guayaquil, Ecuador, and an MBA in International Business from the University of South Carolina.

Shannon Strom, PhD

Senior Vice President of Regulatory Affairs

Shannon Strom, PhD is the Senior Vice President of Regulatory Affairs at Aerogen® Pharma, where she provides strategic global regulatory expertise for the company’s combination biologics products.   With over 20 years of experience at the intersection of regulatory affairs, quality management, and scientific strategy - particularly in respiratory and combination products - her experience underscores her ability to shape scientific and regulatory strategy at the highest level. 
Prior to joining Aerogen Pharma, Shannon served as the Vice President of Regulatory Affairs and Quality at Satsuma Pharmaceuticals.  During her tenure, she spearheaded the company’s regulatory and scientific strategies and led the US new drug application filing for the company’s lead product. 
Earlier in her career, Shannon was involved in the planning, filing, and approval of multiple respiratory products, including Bevespi® and Breztri®.
Shannon’s education includes a BS in Biology from Duke University and a PhD in Pharmacology from UNC Chapel Hill.

Dan W. Burgess 

Senior Director of Quality 

Dan W. Burgess serves as the Senior Director of Quality at Aerogen® Pharma where he plays a pivotal role in developing and implementing the quality strategy for drug/ device combination products.  Dan has over 35 years of experience in the pharmaceutical and medical device industries in both US and international markets, bringing extensive knowledge to the team.
Prior to joining Aerogen Pharma, Dan served as the Vice President of Quality Assurance at Verona Pharma.  In that role, Dan led the development of their quality systems as they grew through phase 3 clinical stage and successful pre-approval inspection, NDA approval and launch of OhtuvayreTM (ensifentrine), a dual LDE3 and PDE4 inhibitor for the treatment of COPD.  Before this, Dan held senior global quality roles at Novavax, Pharm-Olam, Hospira, Alexion and Pfizer.
During his free time, Dan developed innovative quality systems for start-up companies.  He established a company to offer these systems, aiding emerging tech firms in managing the complex quality requirements of the pharmaceutical industry.  He also developed an IAOCR certified GCP audit training program to enhance clinical quality auditors effectiveness.
Dan’s education includes a BSc in Chemistry/ Biology and he is recognized as a Fellow in Research Quality Assurance.